Brexanolone (Zulresso) is approved for postpartum depression.

Brexanolone (Zulresso) is approved for postpartum depression.

• A. True
• B. False
• C. Only for severe postpartum depression
• D. Not approved for postpartum mood disorders

Answer: (A)

Brexanolone (Zulresso) is approved for postpartum depression. It’s a neurosteroid that modulates GABA-A receptors and was developed specifically to treat postpartum depression in adults. The FDA approval designates this indication and requires administration as a 60-hour IV infusion in a monitored healthcare setting due to risks like substantial sedation or loss of consciousness, especially when combined with other central nervous system depressants. Because the label covers postpartum depression in adults (not a broad, non-specific postpartum mood issue and not limited only to the most severe cases), the statement is true.

Brexanolone (Zulresso) is approved for postpartum depression. It’s a neurosteroid that modulates GABA-A receptors and was developed specifically to treat postpartum depression in adults. The FDA approval designates this indication and requires administration as a 60-hour IV infusion in a monitored healthcare setting due to risks like substantial sedation or loss of consciousness, especially when combined with other central nervous system depressants. Because the label covers postpartum depression in adults (not a broad, non-specific postpartum mood issue and not limited only to the most severe cases), the statement is true.